Table 2 |
||||||||
|
Main baseline features in the eight patients meeting ASAS criteria [32] for peripheral spondyloarthritis |
||||||||
|
Patient 14 |
Patient 15 |
Patient 16 |
Patient 17 |
Patient 18 |
Patient 19 |
Patient 20 |
Patient 21 |
|
|
|
||||||||
|
Type of SpA |
AS |
AS |
AS |
AS |
uSpA |
uSpA |
PsA |
PsA |
|
Sacroiliitis |
Grade 2 |
Grade 3 |
Grade 3 |
Grade 3 |
Grade 0 |
Grade 1 |
Grade 0 |
Grade 0 |
|
HLA-B27 |
+ |
- |
+ |
+ |
+ |
+ |
- |
- |
|
Gender |
Male |
Female |
Male |
Female |
Female |
Female |
Female |
Female |
|
Disease duration (years) |
8 |
15 |
19 |
6 |
10 |
10 |
10 |
20 |
|
Main articular and extraarticular symptoms |
Coxitis, arthritis |
Arthritis |
Arthritis, uveitis |
Peripheral enthesitis (Achilles tendon, knee, elbow), arthritis, chest pain |
Arthritis |
Arthritis, IBD, uveitis |
Arthritis, dactylitis, psoriasis, uveitis |
Arthritis, psoriasis |
|
Concomitant NSAIDs/steroids (dosage) |
Yes/no |
No/yes (20 mg/day) |
Yes/yes (5 mg/day) |
Yes/yes (15 mg/day) |
Yes/yes (8 mg/day) |
No/yes (10 mg/day) |
Yes/yes (20 mg/day) |
Yes/yes (20 mg/day) |
|
Concomitant DMARDs |
Methotrexate |
No |
Methotrexate |
Leflunomide |
Methotrexate |
Methotrexate |
Methotrexate |
Methotrexate |
|
Previous biologics other than anti-TNF |
No |
Anakinra |
No |
Abatacept |
No |
No |
No |
No |
|
|
||||||||
|
AS, ankylosing spondylitis meeting modified New York criteria [33]; ASAS, Assessment of SpondyloArthritis International Society; DMARD, disease-modifying antirheumatic drug; IBD, inflammatory bowel disease; NSAID, nonsteroidal anti-inflammatory drug; PsA, psoriatic arthritis meeting Classification Criteria for Psoriatic Arthritis [36]; SpA, spondyloarthritis; uSpA, undifferentiated spondyloarthritis. |
||||||||
|
Lekpa et al. Arthritis Research & Therapy 2012 14:R53 doi:10.1186/ar3766 |
||||||||
